{"name":"CAR-T (Shanghai) Biotechnology Co., Ltd.","slug":"car-t-shanghai-biotechnology-co-ltd","ticker":"","exchange":"","domain":"","description":"In biology, chimeric antigen receptors (CARs)—also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors—are receptor proteins that have been engineered to give T cells the new ability to target a specific antigen. The receptors are chimeric in that they combine both antigen-binding and T cell activating functions into a single receptor.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOLVlJc3JXdTZCR3pKMHhLclJMV0NhYksyQzJjZm5vOENGSUFQRzFIdHBvdzFvYXB3a3pSWGQ3RWtHZEpHMEJJcHZJXy1HdnNsejQ3TzV0bmZoenBMeFBCbjZwWERaekl3ZVJ4amcxNDlkZzJlM2V4VXgwLVdKSnhXYzFMSUVtcUkzNHlTei1IM254eF9TeHBQZzJR?oc=5","date":"2026-04-06","type":"trial","source":"openPR.com","summary":"Knee Osteoarthritis Clinical Trial Pipeline Appears Robust - openPR.com","headline":"Knee Osteoarthritis Clinical Trial Pipeline Appears Robust","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxObTN3R1ZmTjJIbjNzQkFDeFBJQ250bnc0MjV5TURWamtOMkNudklJVFE2WU9waW9rdGRkdUhaQWlnNzhLemw1TVdJRnhOcm1FTGowemdtT2R4NzlpdUZZVWFXZndsbUVOaWRLWDNqVURaWVVfNjJiUWVINkkzR3N0bWdOUllXV3ZhTU1wMXRpRXp6MnF2Z2Iwb2szcXNXSVRYWGlyWXE5c1ZrYjNzLWgxZWc0U0U0YU9lTE9fT1Z4WDNpNk15STRmY05ZVExOY3RSdDVNbVJNYmY0SVNTTzNvNjdCWHRPZXlVVVdZV2hNMENzOUdMcU1MUy1YVGkzcHRLT2paTjR6anhyV1p3b0ZaTV9FOU5mamwxeFYyRzY3ZDBscEtu?oc=5","date":"2026-03-17","type":"trial","source":"StreetInsider","summary":"HER2 Positive Breast Cancer Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight - StreetInsider","headline":"HER2 Positive Breast Cancer Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQTUVhd0RKX0pObm16cTVyQVBlalJPcXhaVWU5R0pqb0hrX1hKcWN5UW5DNEprQUxJajBaMDd4SXVoZEJNc1llWkxkS29xeS04aGlkaTIydV9DZFJpOXplZjJxMGR4MUYtbmR6NXU1elhqUElacGhpMDFFbl9YQ2lDOVMtNU0tZG5DU0lnUE4tdjhJa0pqTWpxNA?oc=5","date":"2026-02-09","type":"deal","source":"BioPharma Dive","summary":"Lilly buys ‘in vivo’ CAR-T maker Orna, extending streak of genetic medicine deals - BioPharma Dive","headline":"Lilly buys ‘in vivo’ CAR-T maker Orna, extending streak of genetic medicine deals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNRlU3TW0tTnBzTnJXMGotTkRzNkFqS2FvclNIZGhldkhUVEJILXFVU1pKOTFjemk5WlBDTEpUQUJxUUtfTlBiREZNcHN6ZncyLXp1eXJqU1lSOW15ek51dWIyTG9mTDlCWGVIMlNCLWVaalAzbTBfVWxORk9ucERjbmVJT2xKY3k4eEowcWl4Q1BSc1NOWFdZbzFsaElZNkpBMEM1Sg?oc=5","date":"2026-01-27","type":"pipeline","source":"BioWorld News","summary":"Asia roundup: Shionogi ups Viiv stake, Fosun spinoff plans, more - BioWorld News","headline":"Asia roundup: Shionogi ups Viiv stake, Fosun spinoff plans, more","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQSDBXZ243SnRELU9tTG5VZTBBaUFIQkVwVmJEYW42OGc5emVxOWVhSGlZcng5U1RDZE5IWUM5YUdYRE1VSDBpVFZxTW5iNUF0X29DSUlDa3RBaHpKRmhwODNuU1hlRmEyQzNDLU9VUlVYN29vb3dTZFl1T21FU2FWNXpGZklzS2hZQXNoV21KczXSAZYBQVVfeXFMTmdVSG5xdU5Qa2JKdFpoQWYyaHhkUkxfM1FUdmljWjc5Z2VZYkxxRzhsa0VmZWZXc2h1UWY4MFFibXlwbXplT0VBS2dITk5ya1oxVlRwN3JJUF9fOFkwQlZ5eHB1NmNwRWZQV0NvMVlmSDZka3laZlZTMjNaN1FXdWxiU0hUSC1XckpWb09qRGNVSDI3UXdR?oc=5","date":"2026-01-17","type":"pipeline","source":"BioInformant","summary":"CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide - BioInformant","headline":"CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxNSFFvQXpJSHdtOGVZZDhTMlE1aGlGZnN3c3hOX1N4OUlHOWpxUVBacUhZQ1ZyblREc0NMR2tobjJFaWdJTE5YTHZFa2t5bldpdmJTN25QNWFMR1ExQWtaVjJOaFF6NVVFLTc2VnlLUHNFTFlZUHhLWUpySWlfS2p2dUcyZ3p0VXcwdkpSN2NmV002UlBHYzNjT2tHb25tYmdTT1BsaGk4OUd0RldJV1hndC1FSW9lb3JxSzlOY3FfUXFabVAyYWtVcFVSYVVpNkc0N1dvdXZvOEN2ck9uVFdvTDhqMjVWOUhHZ3c1Y0F2Q3d5ZW9hd1VmN29n?oc=5","date":"2026-01-13","type":"pipeline","source":"South China Morning Post","summary":"Biotech disruptor pushes cancer-targeting cell and gene therapies beyond boundaries - South China Morning Post","headline":"Biotech disruptor pushes cancer-targeting cell and gene therapies beyond boundaries","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE00UElqdzNTMUdwUHF5QkZfcFY1dGpXT25JV3hPSHphRlVTS1FySUJuN0ZtWWdHazRSazQyd0YwT2U2SmJUNEl5eWtqcXlCODQtaF8w?oc=5","date":"2025-10-22","type":"pipeline","source":"36 Kr","summary":"Shanghai's Biomedical Industry Nears One-Trillion-Yuan Mark in Scale - 36 Kr","headline":"Shanghai's Biomedical Industry Nears One-Trillion-Yuan Mark in Scale - 36 Kr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE8wWk1YNUM2V0dHMS16MWx4MVhFcVljU0hKRDBfNWFZYjAyV1ZrWVN6elU3bWw3bkxOTWpPQ3I5VXRIV2tOWUFmdUZEMW1oMkNBTzU4Ulh2QjhqZXRGWDNZSFFBU05QMWhjRHlubXFTRjE1VWVaeFNPTUtaUUM?oc=5","date":"2025-06-19","type":"pipeline","source":"ThinkChina","summary":"Chinese biotech is having a ‘DeepSeek moment’ - ThinkChina","headline":"Chinese biotech is having a ‘DeepSeek moment’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE80M1RJRWwxSTR2bTJsMFdsamZ0OEVBZHBCZl9pbmdUWDJnUnR3WFRMdGR5MFRTX2hmUENlc0tfSFBXWF9MM1J2UmQyeTVhaVdXb2YtMWpMcEN0RXplQlpUMHZGQ2JWQWs?oc=5","date":"2025-06-18","type":"pipeline","source":"Science | AAAS","summary":"OX40–heparan sulfate binding facilitates CAR T cell penetration into solid tumors in mice - Science | AAAS","headline":"OX40–heparan sulfate binding facilitates CAR T cell penetration into solid tumors in mice - Science | AAAS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQZUxKUEg5OVdyclNkSjJhRENXeWlJOElSb19EeVJPeDFuZDl0MWprYkh1ck1Wb0g1SUVsVkN6RDlORldaWHFmeDNiMWoycU1UTjlvMFlaMlZJS1E4d0JtT3lDcW52YTZiNXBSY0VxNW5BZ1lzQ2E1VXpTaVpEeDVIYlhIWUhXTzkzYURsWWc1LTM?oc=5","date":"2024-06-27","type":"trial","source":"Clinical Trials Arena","summary":"CAR T cells in lupus: Promising results at EULAR 2024 and emergence of China - Clinical Trials Arena","headline":"CAR T cells in lupus: Promising results at EULAR 2024 and emergence of China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTFByaHdhaURCaDZ1ZkVMOEZILXhjajV5T2VWYzNMRXF0bVNjUTJjaVl3cjdPZTFiT0M2QlQzbnROUGpwX2p1cTRueFEtMnlZamNvY0Z6aU4xV3BTTHNrYWRUTDdJRGN2eTgtZkV6WG43OA?oc=5","date":"2024-04-02","type":"pipeline","source":"Wiley Online Library","summary":"CAR‐T‐cell products in solid tumors: Progress, challenges, and strategies - Qian - 2024 - Interdisciplinary Medicine - Wiley Online Library","headline":"CAR‐T‐cell products in solid tumors: Progress, challenges, and strategies - Qian - 2024 - Interdisciplinary Medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNdXdiNVFWazBkRVBpT1gzVEYweHBVM01nQS0yTmxPaWNtdzMtVmxSU0tVRjExNDBoejNlRTJVQzJRaW1HUXZqOE9ySERaWVJMSHAxN0o1dkdWSFJPdEpaMy02UGMxSklONWtvMmYtY2pLQ0dGcW9tbHNQOUtLTEJ4NDYwRUhpdkxQOHZSX1g3OVR5RGtiN1ZzNUN0UVJmUHNYVVhhUUFjV1FoUXFHU2JqQXR6SGFEcnFUdjVXdWY0a1RpZVB4NU5FVmVtamtvZHFI?oc=5","date":"2023-07-18","type":"regulatory","source":"PR Newswire","summary":"Yikaida CAR-T Cell Therapy Approved as a Second-line Therapy for New Indication - PR Newswire","headline":"Yikaida CAR-T Cell Therapy Approved as a Second-line Therapy for New Indication","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}